Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion

被引:3
作者
Thuss-Patience, PC
Kretzschmar, A
Krenn, V
Dörken, B
Reichardt, P
机构
[1] Humboldt Univ, Charite, Med Klin Schwerpunkt Hamatol & Onkol, D-13353 Berlin, Germany
[2] Humboldt Univ, Charite, Inst Pathol, D-13353 Berlin, Germany
[3] Humboldt Univ, Charite, Robert Rossle Klin, Helios Klinikum Berlin, D-13353 Berlin, Germany
来源
ONKOLOGIE | 2003年 / 26卷 / 01期
关键词
gastric cancer; metastasis; chemotherapy; docetaxel;
D O I
10.1159/000069866
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens. There are good data for the combination regimen ECF (epirubicin, cisplatin and 5-FU), which is therefore often regarded as a reference treatment. Docetaxel shows promising activity against gastric cancer as single agent and in combinations. To develop a well-tolerable combination chemotherapy for an ambulant setting we initiated a randomized phase II study, comparing docetaxel and 5-FU continuous infusion (DF) with ECF. Case Report: A 66-year-old patient with the history of a curatively resected gastric cancer 2 years previously presented with abdominal masses and lesions in his spleen. Histology proved metastases of gastric adenocarcinoma. The patient was treated with docetaxel (75 mg/m(2), d1) and 5-FU continuous infusion (200 mg/m(2)/d, d1-21, q3w) within our study. Already after 2 cycles of chemotherapy he showed symptomatic improvement and partial remission of his tumor, which was confirmed after the 3rd cycle. In our ongoing study so far 50 patients are evaluable for response. Objective tumor response (CR + PR) could be documented in 44% of patients in the DF arm as well as in the ECF arm. Conclusion: Docetaxel and 5-FU continuous infusion is an active regimen which could possibly be used as an alternative to established treatment protocols.
引用
收藏
页码:63 / 65
页数:3
相关论文
共 14 条
  • [1] Burris H A 3rd, 1997, Oncology (Williston Park), V11, P50
  • [2] CHUN HG, 2001, P AN M AM SOC CLIN, V20, pA162
  • [3] CONSTELA M, 1998, P ASCO, V17, pA289
  • [4] Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The eastern cooperative oncology group (ECOG) results of protocol E1293
    Einzig, AI
    Neuberg, D
    Remick, SC
    Karp, DD
    ODwyer, PJ
    Stewart, JA
    Benson, AB
    [J]. MEDICAL ONCOLOGY, 1996, 13 (02): : 87 - 93
  • [5] A PHASE-II STUDY IN ADVANCED GASTROESOPHAGEAL CANCER USING EPIRUBICIN AND CISPLATIN IN COMBINATION WITH CONTINUOUS-INFUSION 5-FLUOROURACIL (ECF)
    FINDLAY, M
    CUNNINGHAM, D
    NORMAN, A
    MANSI, J
    NICOLSON, M
    HICKISH, T
    NICOLSON, V
    NASH, A
    SACKS, N
    FORD, H
    CARTER, R
    HILL, A
    [J]. ANNALS OF ONCOLOGY, 1994, 5 (07) : 609 - 616
  • [6] Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial
    Mavroudis, D
    Kourousis, C
    Androulakis, N
    Kalbakis, K
    Agelaki, S
    Kakolyris, S
    Souglakos, J
    Sarra, E
    Vardakis, N
    Hatzidaki, D
    Sarmonis, G
    Georgoulias, V
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 341 - 344
  • [7] Ross P, 1999, P AN M AM SOC CLIN, V18, p272a
  • [8] DOCETAXEL (TAXOTERE(TM)) IN ADVANCED GASTRIC-CANCER - RESULTS OF A PHASE-II CLINICAL-TRIAL
    SULKES, A
    SMYTH, J
    SESSA, C
    DIRIX, LY
    VERMORKEN, JB
    KAYE, S
    WANDERS, J
    FRANKLIN, H
    LEBAIL, N
    VERWEIJ, J
    [J]. BRITISH JOURNAL OF CANCER, 1994, 70 (02) : 380 - 383
  • [9] TAGUCHI T, 1997, P AN M AM SOC CLIN, V16, pA263
  • [10] THUSSPATIENCE PC, 2002, P AN M AM SOC CLIN, V21, pA162